Casdin Capital 13F holdings, Q1 2016
Holdings as of March 31, 2016 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 25 US equity positions worth $84.5m in its Q1 2016 13F filing. The largest position was LOXO ONCOLOGY INC at 8.1% of the reported book, followed by EPIZYME INC and FOUNDATION MEDICINE INC. Against the Q4 2015 filing, it opened 5 new positions, added to 12 and reduced 6 among the top 25 holdings.
What did Casdin Capital own in Q1 2016? Top 25 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2015 |
|---|---|---|---|---|---|---|---|
| 1 | LOXO ONCOLOGY INC | 8.1% | $6.8m | 250,000 | -1% | reduced | |
| 2 | EPIZYME INC | 7.8% | $6.6m | 545,000 | 64% | added | |
| 3 | FOUNDATION MEDICINE INC | 7.2% | $6.1m | 335,000 | 191% | added | |
| 4 | SG7 SAGE THERAPEUTICS INC | 7.2% | $6.1m | 189,000 | 32% | added | |
| 5 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 7.1% | $6.0m | 148,000 | 53% | added |
| 6 | 2655787D BLUEPRINT MEDICINES CORP | 6.9% | $5.8m | 321,300 | -22% | reduced | |
| 7 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 6.7% | $5.6m | 90,000 | 50% | added |
| 8 | BLUEBIRD BIO INC | 6.0% | $5.1m | 120,000 | 20% | added | |
| 9 | MYOKARDIA INC | 6.0% | $5.1m | 475,350 | 18% | added | |
| 10 | SPARK THERAPEUTICS INC | 5.9% | $5.0m | 170,000 | 17% | added | |
| 11 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 4.9% | $4.1m | 321,023 | 0% | held |
| 12 | KITE PHARMA INC | 4.1% | $3.4m | 75,000 | 150% | added | |
| 13 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 3.5% | $3.0m | 339,362 | 43% | added |
| 14 | EDIT EDITAS MEDICINE INC | Healthcare | 3.5% | $3.0m | 85,470 | – | new |
| 15 | DXCM DEXCOM INC | Healthcare | 3.2% | $2.7m | 40,000 | 135% | added |
| 16 | AVEXIS INC | 2.0% | $1.7m | 63,000 | – | new | |
| 17 | GLOBAL BLOOD THERAPEUTICS IN | 2.0% | $1.7m | 105,000 | 62% | added | |
| 18 | GHDX GENOMIC HEALTH INC | 1.6% | $1.4m | 55,000 | -67% | reduced | |
| 19 | BMY BRISTOL MYERS SQUIBB CO | Healthcare | 1.6% | $1.3m | 21,000 | -35% | reduced |
| 20 | BIIB BIOGEN INC | Healthcare | 1.5% | $1.3m | 5,000 | -44% | reduced |
| 21 | ONC BEIGENE LTD | Healthcare | 1.1% | $953.0k | 32,500 | – | new |
| 22 | IGNYTA INC | 0.9% | $745.0k | 110,000 | – | new | |
| 23 | EXK EXACT SCIENCES CORP | Basic Materials | 0.5% | $404.0k | 60,000 | – | new |
| 24 | MEDIDATA SOLUTIONS INC | 0.5% | $387.0k | 10,000 | 0% | held | |
| 25 | OXFORD IMMUNOTEC GLOBAL PLC | 0.2% | $198.0k | 20,000 | -73% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.